Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders

Drug News and Perspectives

Volumn 18, Issue 9, 2005, Pages 561-566

  Wang, Su Jane ^a   Yang, Tsung Tsair ^a,b  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b CARDINAL TIEN HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DIZOCILPINE; GLUTAMIC ACID; HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE;

ATAXIA; BEHAVIOR DISORDER; DRUG MECHANISM; HUMAN; MEMORY DISORDER; MENTAL DISEASE; MUSCLE RELAXATION; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE; GLUTAMIC ACID; HUMANS; MENTAL DISORDERS; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 32844454441     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2005.18.9.953668     Document Type: Review

References (45)

1. Carlsson, A., Waters, N., Holm-Waters, S. et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol 2001, 41: 237-60.
2. Seeman, P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987, 1: 133-52.
3. Stockmeier, C.A., DiCarlo, J.J., Zhang, Y. et al. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 1993, 266: 1374-84.
4. Davis, K.L., Kahn, R.S., Ko, G. et al. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 1991, 148: 1474-86.
5. Carlsson, M. and Carlsson, A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990, 13: 272-6.
6. Lidsky, T.I., Yablonsky-Alter, E., Zuck, L. et al. Anti-glutamatergic effects of clozapine. Neurosci Lett 1993, 163: 155-8.
7. Banerjee, S.P., Zuck, L.G., Yablonsky-Alter, E. et al. Glutamate agonist activity: Implications for antipsychotic drug action and schizophrenia. Neuroreport 1995, 6: 2500-4.
8. Lidsky, T.I., Yablonsky-Alter, E., Zuck, L.G. et al. Antipsychotic drug effects on glutamatergic activity. Brain Res 1997, 764: 46-52.
9. Toru, M., Watanabe, S., Shibuya, H. et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 1988, 78: 121-37.
10. Tsai, G., van Kammen, D.P., Chen, S. et al. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry 1998, 44: 667-74.
11. Javitt, D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004, 9: 984-97.
12. Heresco-Levy, U. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27: 1113-23.
13. Wroblewski, J.T. and Danysz, W. Modulation of glutamate receptors: Molecular mechanisms and functional implications. Annu Rev Pharmacol Toxicol 1989, 29: 441-74.
14. Choi, D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988, 1: 623-34.
15. Meldrum, B. and Garthwaite, J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol 1990, 11: 379-87.
16. Danysz, W., Parsons, C.G., Bresnick, I. et al. Glutamate in CNS disorders. Drug News Perspect 1996, 8: 261-77.
17. Goff, D.C. and Coyle, J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001, 158: 1367-77.
18. Nakanishi, S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992, 258: 597-603.
19. Conn, P.J. and Pin, J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997, 37: 205-37.
20. Kim, J.S., Kornhuber, H.H., Schmid-Burgk, W. et al. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980, 20: 379-82.
21. Toru, M., Kurumaji, A., Kumashiro, S. et al. Excitatory amino acidergic neurons in chronic schizophrenic brain. Mol Neuropharmacol 1992, 2: 241-3.
22. Macciardi, F., Lucca, A., Catalano, M. et al. Amino acid patterns in schizophrenia: Some new findings. Psychiatry Res 1990, 32: 63-70.
23. Kristensen, J.D., Svensson, B., Gordh, T. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain 1992, 51: 249-53.
24. Jentsh, J.D. and Roth, R.H. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropharmacology 1999, 20: 201-25.
25. Meador-Woodruff, J.H., King, R.E., Damask, S.P. et al. Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine. Mol Psychiatry 1996, 1: 41-53.
26. Meador-Woodruff, J.H. and Healy, D.J. Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 2000, 31: 288-94.
27. Gattaz, W.F., Gattaz, D., Beckmann, H. Glutamate in schizophrenics and healthy controls. Arch Psychiatr Nervenkr 1982, 231: 221-5.
28. Perry, T.L. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett 1982, 28: 81-5.
29. Gattaz, W.F., Gasser, T. and Beckmann, H. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biol Psychiatry 1985, 20: 360-6.
30. Korpi, E.R., Kaufmann, C.A., Marnela, K.M. et al. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res 1987, 20: 337-45.
31. Carlsson, M.L., Engberg, G. and Carlsson, A. Effects of D-cycloserine and (+)-HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice. J Neural Transm Gen Sect 1994, 95: 223-33.
32. Cascella, N.G., Macciardi, F., Cavallini, C. et al. D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label study. J Neural Transm Gen Sect 1994, 95: 105-11.
33. Moghaddam, B. and Adams, B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281: 1349-52.
34. Mathe, J.M., Fagerquist, M.V. and Svensson, T.H. Antipsychotic-like effect of the AMPA receptor antagonist LY326325 as indicated by suppression of conditioned avoidance response in the rat. J Neural Transm 1999, 106: 1003-9.
35. Yang, T.T. and Wang, S.J. Effects of haloperidol and clozapine on glutamate release from nerve terminals isolated from rat prefrontal cortex. Synapse 2005, 56: 12-20.
36. Daly, D.A. and Moghaddam, B. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 1993, 152: 61-4.
37. Bardgett, M.E., Wrona, C.T., Newcomer, J.W. et al. Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur J Pharmacol 1993, 230: 245-50.
38. Yamamoto, B.K., Pehek, E.A. and Meltzer, H.Y. Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 1994, 55 Suppl B: 8-14.
39. Yamamoto, B.K. and Cooperman, M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 1994, 14: 4159-66.
40. See, R.E. and Chapman, M.A. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur J Pharmacol 1994, 263: 269-76.
41. Pietraszek, M., Golembiowska, K., Bijak, M. et al. Different effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: Microdialysis and electrophysiological studies. Naunyn Schmied Arch Pharmacol 2002, 366: 417-24.
42. Arvanov, V.L., Liang, X., Schwartz, J. et al. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 1997, 283: 226-34.
43. Riva, M.A., Tascedda, F., Lovati, E. et al. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res Mol Brain Res 1997, 50: 136-42.
44. McCoy, L. and Richfield, E.K. Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci Lett 1996, 213: 137-41.
45. Bleich, S., Romer, K., Wiltfang, J. et al. Glutamate and the glutamate receptor system: A target for drug action. Int J Geriatr Psychiatry 2003, 18: 533-40.